Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

A key hormone in the fetal liver has been found for the first time to play a critical role in determining iron endowment in the newborn baby.

© Samira Lakhal-Littleton

Up until now, widely held notions made in comparison to how the adult liver controls iron in the body have led to a common focus on how maternal iron status and function of the placenta determines a baby's iron status. A new study from the Lakhal-Littleton research group in the Department of Physiology, Anatomy & Genetics reveals a more autonomous process takes place within the fetus than previously understood.

Historically, research into iron has focused on its role in the synthesis of haemoglobin, the substance in red blood cells that carries oxygen from your lungs throughout your body. However, in recent years evidence has been uncovered that iron plays an important role in many other physiological processes. For example, iron deficiency has been shown to impair cardiovascular function independently of haemoglobin levels in key Lakhal-Littleton lab papers in eLife and PNAS. In infancy, iron deficiency is associated with growth retardation and both motor skill and cognitive defects, because iron is required for the synthesis of myelin, an essential component of neurons, and also for rapid bone and muscle growth during childhood. While it is known that a liver-derived hormone called Hepcidin is responsible for regulating iron in the body, what is not well understood is the role it plays in the development of the unborn baby during pregnancy.

Read more on the Department of Physiology, Anatomy & Genetics website

Similar stories

Latest data on immune response to COVID-19 reinforces need for vaccination, says Oxford-led study

A new study led by the University of Oxford has found that previous infection, whether symptomatic or asymptomatic, does not necessarily protect you long-term from COVID-19, particularly against new Variants of Concern.

First trimester placental scan - Artificial Intelligence in Health and Care Award

A first trimester 3D placental ultrasound scan which can predict fetal growth restriction and pre-eclampsia, could become part of a woman's routine care thanks to a new Artificial Intelligence in Health and Care Award.

Impaired antibody response to COVID-19 vaccination in patients with myeloid blood cancers

Oxford researchers have found that antibody responses to the first doses of COVID-19 vaccine in people with chronic myeloid blood cancers are not as strong as those among the general population.

Treating Needle Fears May Reduce COVID-19 Vaccine Hesitancy Rates by 10%

A new large-scale study shows that a quarter of the UK adult population screens positive for a potential injection phobia.

RECOVERY trial Regeneron’s monoclonal antibody combination reduces deaths for hospitalised COVID-19 patients

The Randomised Evaluation of COVID-19 Therapy (RECOVERY) trial has demonstrated that the investigational antibody combination developed by Regeneron reduces the risk of death when given to patients hospitalised with severe COVID-19 who have not mounted a natural antibody response of their own.

Major new study could help protect millions of people with type 2 diabetes from cardiovascular disease

A new study led by the Nuffield Department of Population Health at the University of Oxford will research whether a daily tablet could help protect the millions of people worldwide with type 2 diabetes from developing cardiovascular disease.